PedAM

Pediatric Disease Annotations & Medicines

Disease	neuropathy
Phenotype	C0006142\|breast cancer
Sentences	8
PubMedID- 22851566	Therefore, we sought to determine whether neuropathy was associated with breast cancer recurrence in a clinical trial population who received adjuvant taxane therapy.
PubMedID- 26374076	Correction: replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel-letter.
PubMedID- 23204130	Experimental design: a gwas of paclitaxel-induced cytotoxicity was conducted in 247 lcls from the hapmap project and compared with a gwas of sensory peripheral neuropathy in patients with breast cancer (n = 855) treated with paclitaxel in the cancer and leukemia group b (calgb) 40101 trial.
PubMedID- 26133777	Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel--response.
PubMedID- 24599932	Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel.
PubMedID- 25596818	A phase ii randomized trial that will assess the effects of acupuncture in preventing dose reductions due to chemotherapy-induced peripheral neuropathy in patients with breast cancer is currently ongoing (clinicaltrials.gov identifier nct01881932).
PubMedID- 26133776	Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel--letter.
PubMedID- 22886073	At the dose used in this study (40 mg/m2 every 3 weeks, the approved regimen in breast cancer), the incidence of peripheral sensory neuropathy and fatigue was consistent with rates seen in clinical trials of other tumor types and in other studies of recurrent disease, including breast cancer [19, 20] and endometrial carcinoma [27].

Page: 1